Récap de la semaine du 22 janvier

Sanofi will buy Bioverativ in an $11.6bn deal. Bioverativ’s acquisition price values its shares at a 64% premium over their closing price last Friday, which underlines Sanofi’s confidence in the target’s haemophilia treatments. The move is Sanofi’s biggest acquisition in seven years, particularly after the company’s efforts to purchase Medivation and Actelion fell through in … Lire la suite Récap de la semaine du 22 janvier